KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

AbCellera Biologics (ABCL) Receivables Refunds (2020 - 2022)

AbCellera Biologics (ABCL) has disclosed Receivables Refunds for 2 consecutive years, with $64.8 million as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Receivables Refunds rose 353.84% year-over-year to $64.8 million, compared with a TTM value of $64.8 million through Dec 2022, up 353.84%, and an annual FY2022 reading of $64.8 million, up 353.84% over the prior year.
  • Receivables Refunds was $64.8 million for Q4 2022 at AbCellera Biologics, up from $14.3 million in the prior quarter.
  • Across five years, Receivables Refunds topped out at $64.8 million in Q4 2022 and bottomed at $14.3 million in Q4 2021.